Flow chart showing an overview of the study. Patients with breast, melanoma, pancreatic, prostate or ovarian tumors tested for BRCA1 and BRCA2 gene mutation.
Abbreviations: PVs, pathogenic variants; VUS, variants of uncertain significance; WT, wild-type BRCA1/2 sequence.